Literature DB >> 26460041

A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Bryan A Smith1, Artem Sokolov2, Vladislav Uzunangelov3, Robert Baertsch2, Yulia Newton3, Kiley Graim3, Colleen Mathis1, Donghui Cheng4, Joshua M Stuart5, Owen N Witte6.   

Abstract

Evidence from numerous cancers suggests that increased aggressiveness is accompanied by up-regulation of signaling pathways and acquisition of properties common to stem cells. It is unclear if different subtypes of late-stage cancer vary in stemness properties and whether or not these subtypes are transcriptionally similar to normal tissue stem cells. We report a gene signature specific for human prostate basal cells that is differentially enriched in various phenotypes of late-stage metastatic prostate cancer. We FACS-purified and transcriptionally profiled basal and luminal epithelial populations from the benign and cancerous regions of primary human prostates. High-throughput RNA sequencing showed the basal population to be defined by genes associated with stem cell signaling programs and invasiveness. Application of a 91-gene basal signature to gene expression datasets from patients with organ-confined or hormone-refractory metastatic prostate cancer revealed that metastatic small cell neuroendocrine carcinoma was molecularly more stem-like than either metastatic adenocarcinoma or organ-confined adenocarcinoma. Bioinformatic analysis of the basal cell and two human small cell gene signatures identified a set of E2F target genes common between prostate small cell neuroendocrine carcinoma and primary prostate basal cells. Taken together, our data suggest that aggressive prostate cancer shares a conserved transcriptional program with normal adult prostate basal stem cells.

Entities:  

Keywords:  RNA-seq; basal cell; neuroendocrine prostate cancer; prostate cancer; stem cell signature

Mesh:

Substances:

Year:  2015        PMID: 26460041      PMCID: PMC4664352          DOI: 10.1073/pnas.1518007112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  73 in total

Review 1.  A perspective on cancer cell metastasis.

Authors:  Christine L Chaffer; Robert A Weinberg
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

2.  Apolipoprotein D expression in benign and malignant prostate tissues.

Authors:  J C Rodríguez; M Díaz; L O González; J Sánchez; M T Sánchez; A M Merino; F Vizoso
Journal:  Int J Surg Investig       Date:  2000

3.  Molecular classification of prostate cancer using curated expression signatures.

Authors:  Elke K Markert; Hideaki Mizuno; Alexei Vazquez; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

6.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

7.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

Review 8.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

9.  SOX2 expression in the developing, adult, as well as, diseased prostate.

Authors:  X Yu; J M Cates; C Morrissey; C You; M M Grabowska; J Zhang; D J DeGraff; D W Strand; O E Franco; O Lin-Tsai; S W Hayward; R J Matusik
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-08-05       Impact factor: 5.554

10.  Comparison of software packages for detecting differential expression in RNA-seq studies.

Authors:  Fatemeh Seyednasrollah; Asta Laiho; Laura L Elo
Journal:  Brief Bioinform       Date:  2013-12-02       Impact factor: 11.622

View more
  96 in total

1.  Advanced neuroendocrine prostate tumors regress to stemness.

Authors:  Leigh Ellis; Massimo Loda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-17       Impact factor: 11.205

2.  Evasion of targeted cancer therapy through stem-cell-like reprogramming.

Authors:  Kristine M Wadosky; Leigh Ellis; David W Goodrich
Journal:  Mol Cell Oncol       Date:  2017-02-16

3.  ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.

Authors:  Chen-Ying Liu; Tong Yu; Yuji Huang; Long Cui; Wanjin Hong
Journal:  J Biol Chem       Date:  2017-04-13       Impact factor: 5.157

4.  Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.

Authors:  Chun-Peng Liao; Leng-Ying Chen; Andrea Luethy; Youngsoo Kim; Kian Kani; A Robert MacLeod; Mitchell E Gross
Journal:  Endocr Relat Cancer       Date:  2017-04       Impact factor: 5.678

5.  ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Authors:  Rohit Bose; Wouter R Karthaus; Joshua Armenia; Wassim Abida; Phillip J Iaquinta; Zeda Zhang; John Wongvipat; Elizabeth V Wasmuth; Neel Shah; Patrick S Sullivan; Michael G Doran; Ping Wang; Anna Patruno; Yilin Zhao; Deyou Zheng; Nikolaus Schultz; Charles L Sawyers
Journal:  Nature       Date:  2017-06-14       Impact factor: 49.962

6.  Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.

Authors:  Imran Ahmad; Ernest Mui; Laura Galbraith; Rachana Patel; Ee Hong Tan; Mark Salji; Alistair G Rust; Peter Repiscak; Ann Hedley; Elke Markert; Carolyn Loveridge; Louise van der Weyden; Joanne Edwards; Owen J Sansom; David J Adams; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

7.  v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Authors:  Xiaoming Ju; Xuanmao Jiao; Adam Ertel; Mathew C Casimiro; Gabriele Di Sante; Shengqiong Deng; Zhiping Li; Agnese Di Rocco; Tingting Zhan; Adam Hawkins; Tanya Stoyanova; Sebastiano Andò; Alessandro Fatatis; Michael P Lisanti; Leonard G Gomella; Lucia R Languino; Richard G Pestell
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

Review 8.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

9.  The Sca-1+ and Sca-1- mouse prostatic luminal cell lineages are independently sustained.

Authors:  Oh-Joon Kwon; Jong Min Choi; Li Zhang; Deyong Jia; Zhouyihan Li; Yiqun Zhang; Sung Yun Jung; Chad J Creighton; Li Xin
Journal:  Stem Cells       Date:  2020-08-08       Impact factor: 6.277

Review 10.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.